UA130334C2 - Способи лікування астми за допомогою антитіла до tslp - Google Patents

Способи лікування астми за допомогою антитіла до tslp

Info

Publication number
UA130334C2
UA130334C2 UAA201911056A UAA201911056A UA130334C2 UA 130334 C2 UA130334 C2 UA 130334C2 UA A201911056 A UAA201911056 A UA A201911056A UA A201911056 A UAA201911056 A UA A201911056A UA 130334 C2 UA130334 C2 UA 130334C2
Authority
UA
Ukraine
Prior art keywords
tslp
methods
antibody
treating asthma
asthma
Prior art date
Application number
UAA201911056A
Other languages
English (en)
Ukrainian (uk)
Inventor
Джейн Р. Парнес
Джанет Ґріффітс
Джанет Гриффитс
Original Assignee
Емджен Інк.
Эмджен Инк.
Медіммун Елелсі
Медиммун Элэлси
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Емджен Інк., Эмджен Инк., Медіммун Елелсі, Медиммун Элэлси filed Critical Емджен Інк.
Publication of UA130334C2 publication Critical patent/UA130334C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
UAA201911056A 2017-04-12 2018-04-12 Способи лікування астми за допомогою антитіла до tslp UA130334C2 (uk)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762484864P 2017-04-12 2017-04-12
US201762553477P 2017-09-01 2017-09-01
US201762553575P 2017-09-01 2017-09-01
PCT/US2018/027271 WO2018191479A1 (en) 2017-04-12 2018-04-12 Treatment of asthma with anti-tslp antibody

Publications (1)

Publication Number Publication Date
UA130334C2 true UA130334C2 (uk) 2026-01-28

Family

ID=62092313

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201911056A UA130334C2 (uk) 2017-04-12 2018-04-12 Способи лікування астми за допомогою антитіла до tslp

Country Status (22)

Country Link
US (3) US10828365B2 (enExample)
EP (1) EP3609917A1 (enExample)
JP (4) JP7330896B2 (enExample)
KR (2) KR102666879B1 (enExample)
CN (1) CN110573525A (enExample)
AU (2) AU2018253118B2 (enExample)
BR (1) BR112019021482A2 (enExample)
CA (1) CA3059364A1 (enExample)
CL (1) CL2019002897A1 (enExample)
CO (1) CO2019011462A2 (enExample)
IL (1) IL269791B (enExample)
JO (1) JOP20190243B1 (enExample)
MX (1) MX2019012158A (enExample)
MY (1) MY207509A (enExample)
PE (1) PE20200484A1 (enExample)
PH (1) PH12019502331A1 (enExample)
SG (1) SG11201909322VA (enExample)
TN (1) TN2019000289A1 (enExample)
TW (2) TW202523688A (enExample)
UA (1) UA130334C2 (enExample)
UY (1) UY37676A (enExample)
WO (1) WO2018191479A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20210650T1 (hr) * 2015-09-09 2021-05-28 Novartis Ag Protutijela koja vežu timusni stromalni limfopoetin (tslp) i postupci uporabe protutijela
KR102666879B1 (ko) * 2017-04-12 2024-05-23 암젠 인크 항-tslp 항체를 이용한 천식의 치료
JP7628966B2 (ja) 2019-06-04 2025-02-12 ジエンス ヘンルイ メデイシンカンパニー リミテッド 胸線間質性リンパ球増殖因子に結合可能な抗体およびその使用
CA3147044A1 (en) * 2019-07-11 2021-01-14 Tavotek Biotherapeutics (Hong Kong) Limited Agents that interfere with thymic stromal lymphopoietin (tslp)-receptor signaling
EP4025602A4 (en) * 2019-09-04 2023-12-13 Biosion, Inc. TSLP BINDING ANTIBODIES AND USES THEREOF
PH12022551022A1 (en) * 2019-10-28 2023-03-06 Medimmune Ltd Dry powder formulations of thymic stromal lymphopoietin (tslp)-binding antibodies and methods of use thereof
CN114887053B (zh) * 2019-11-29 2026-04-24 康诺亚生物医药科技（成都）有限公司 一种tslp相关病症治疗剂的开发和应用
AU2020400221A1 (en) * 2019-12-13 2022-05-19 Harbour Biomed (Shanghai) Co., Ltd. Anti-TSLP antibody and uses thereof
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法
EP4103605A1 (en) * 2020-02-13 2022-12-21 Amgen Inc. Treatment of atopic dermatitis with anti-tslp antibody
MX2022010012A (es) * 2020-02-13 2022-09-07 Amgen Inc Formulaciones de anticuerpos anti-tslp humanos y métodos de tratamiento de una enfermedad inflamatoria.
IL295511A (en) * 2020-02-18 2022-10-01 Amgen Inc Formulations of human anti-tslp antibodies and methods of using them
CN113388035B (zh) * 2020-03-13 2026-02-27 迈威(上海)生物科技股份有限公司 特异性针对人tslp的抗体及其应用
WO2022117079A1 (zh) * 2020-12-03 2022-06-09 江苏恒瑞医药股份有限公司 结合胸腺基质淋巴细胞生成素的抗体及其应用
CN113501878B (zh) * 2021-02-03 2022-12-02 北京智仁美博生物科技有限公司 针对人tslp的多种抗体及其用途
CN114853888B (zh) * 2021-02-05 2023-11-03 上海洛启生物医药技术有限公司 抗tslp纳米抗体及其应用
EP4302778A4 (en) * 2021-03-03 2025-03-12 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. PHARMACEUTICAL COMPOSITION CONTAINING AN ANTI-TSLP ANTIBODY
PH12023552762A1 (en) * 2021-04-19 2024-04-15 Medimmune Ltd An anti-tslp fab with improved stability
KR20230175245A (ko) 2021-04-23 2023-12-29 암젠 인크 변형된 항-tslp 항체
EP4326766A1 (en) * 2021-04-23 2024-02-28 Amgen Inc. Anti-tslp antibody compositions and uses thereof
CN113683694B (zh) * 2021-09-03 2022-05-13 江苏荃信生物医药股份有限公司 一种抗人tslp单克隆抗体及其应用
CN117209603B (zh) * 2021-12-02 2024-02-27 北京东方百泰生物科技股份有限公司 一种抗tslp的单克隆抗体、其抗原结合片段及其应用
CN117327176A (zh) * 2022-06-24 2024-01-02 南京融捷康生物科技有限公司 一种抗tslp的单域抗体及其用途
US12110324B2 (en) 2022-07-22 2024-10-08 Flagship Pioneering Innovations Vi, Llc Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP)
TW202426485A (zh) 2022-10-26 2024-07-01 美商安進公司 抗ｔｓｌｐ抗體組成物及其用途
WO2025049343A1 (en) * 2023-08-25 2025-03-06 Proteologix Us Inc. Anti-tslp antibody constructs and uses thereof
AU2024334289A1 (en) 2023-08-25 2026-04-09 Proteologix Us Inc. Anti-il-13 multispecific antibody constructs and uses thereof
CN117551195B (zh) * 2024-01-12 2024-04-09 杭州畅溪制药有限公司 靶向tslp的vhh纳米抗体及其应用
WO2025179220A1 (en) * 2024-02-22 2025-08-28 Flagship Pioneering Innovations Vi, Llc Dosing of antigen binding molecules targeting thymic stromal lymphopoietin (tslp)
WO2025264860A2 (en) 2024-06-18 2025-12-26 Yale University Methods of treating post-covid airway disease
US20260098100A1 (en) * 2024-10-04 2026-04-09 Prana Therapies, Inc. Il-4r and tslp inhibitors and methods of use thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
US7982016B2 (en) * 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
US8359965B2 (en) 2007-09-17 2013-01-29 Oxford J Craig Apparatus and method for broad spectrum radiation attenuation
UY32038A (es) 2008-08-08 2010-03-26 Glaxo Wellcome Mfg Pte Ltd Inmunoblobulinas anti-cd127 y sus usos
ES2784123T3 (es) 2009-11-04 2020-09-22 Merck Sharp & Dohme Anticuerpo anti TSLP genomodificado
WO2012007495A1 (en) 2010-07-15 2012-01-19 F. Hoffmann-La Roche Ag Antibodies specifically binding to human tslpr and methods of use
US9100245B1 (en) 2012-02-08 2015-08-04 Amazon Technologies, Inc. Identifying protected media files
US9306926B2 (en) 2013-03-15 2016-04-05 Brian A. Truong User authentication using unique hidden identifiers
AR098155A1 (es) * 2013-10-23 2016-05-04 Genentech Inc Métodos para diagnosticar y tratar trastornos eosinofílicos
CA2955086A1 (en) * 2014-08-08 2016-02-11 Alector Llc Anti-trem2 antibodies and methods of use thereof
KR20170123315A (ko) * 2015-03-11 2017-11-07 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 Tslp 결합 단백질
EA038332B1 (ru) 2015-09-09 2021-08-10 Новартис Аг Молекулы, связывающиеся с тимусным стромальным лимфопоэтином (tslp), и способы применения таких молекул
KR102666879B1 (ko) * 2017-04-12 2024-05-23 암젠 인크 항-tslp 항체를 이용한 천식의 치료

Also Published As

Publication number Publication date
CA3059364A1 (en) 2018-10-18
AU2018253118B2 (en) 2025-04-10
CO2019011462A2 (es) 2019-10-31
JP2025170430A (ja) 2025-11-18
IL269791A (en) 2019-11-28
WO2018191479A1 (en) 2018-10-18
MY207509A (en) 2025-02-28
KR102666879B1 (ko) 2024-05-23
TW201838652A (zh) 2018-11-01
US20210052726A1 (en) 2021-02-25
CL2019002897A1 (es) 2020-03-06
BR112019021482A2 (pt) 2020-05-12
US20250032608A1 (en) 2025-01-30
AU2018253118A1 (en) 2019-10-24
KR20240070727A (ko) 2024-05-21
AU2025204735A1 (en) 2025-07-17
JP2023099233A (ja) 2023-07-11
KR20190140956A (ko) 2019-12-20
JP7330896B2 (ja) 2023-08-22
SG11201909322VA (en) 2019-11-28
JOP20190243A1 (ar) 2019-10-13
JP2020516647A (ja) 2020-06-11
TN2019000289A1 (en) 2021-05-07
PE20200484A1 (es) 2020-03-03
US10828365B2 (en) 2020-11-10
JP2024150751A (ja) 2024-10-23
IL269791B (en) 2022-07-01
US20180296669A1 (en) 2018-10-18
JOP20190243B1 (ar) 2024-12-22
PH12019502331A1 (en) 2020-09-28
MX2019012158A (es) 2019-12-16
UY37676A (es) 2018-10-31
TW202523688A (zh) 2025-06-16
EP3609917A1 (en) 2020-02-19
CN110573525A (zh) 2019-12-13
TWI856945B (zh) 2024-10-01

Similar Documents

Publication Publication Date Title
UA130334C2 (uk) Способи лікування астми за допомогою антитіла до tslp
MX2022012749A (es) Moleculas de union a linfopoyetina estromal timica (tslp) y metodos de uso de las moleculas.
EA201890655A1 (ru) Молекулы, связывающиеся с тимусным стромальным лимфопоэтином (tslp), и способы применения таких молекул
MX2023013729A (es) Receptores quimericos de flt3 y metodos de uso de los mismos.
MX2020013421A (es) Composiciones de dióxido de silicio de carbono poroso biogénico, métodos de elaboracion y uso de estas.
PH12020551710A1 (en) Anti-hla-g antibodies and use thereof
EP4335874A3 (en) Anti-hla-g antibodies and use thereof
MX372658B (es) Anticuerpos anti-cd3 y metodos de uso.
BR112017008710A8 (pt) Composições e métodos para estimular a eficácia de imunoterapia celular adotiva
MX393951B (es) Anticuerpos antisortilina y métodos para su uso.
GEAP202215554A (en) Pd-1-binding molecules and methods of use thereof
EA201592213A1 (ru) Антитела антирецептор трансферрина и способы их использования
EA202090632A1 (ru) Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
MX2017007196A (es) Fibroblastos de embrion de pollo inmortalizados.
MX379312B (es) Anticuerpos especificos para fcrn.
MX2020010722A (es) Anticuerpos anti-cd40 para uso en la prevencion del rechazo de injertos.
CL2023003432A1 (es) Fragmento de union fab de igg1 del anticuerpo anti-tslp
Wang et al. New results on passivity analysis of memristor-based neural networks with time-varying delays
MX2015010023A (es) Anticuerpos anti-cd83 y su uso.
MX2021008983A (es) Atributos de aflibercept y metodos de caracterizacion y modificacion de los mismos.
MX2023009584A (es) Anticuerpos monoclonales anti-chinches y metodos de elaboracion y usos de los mismos.
PE20171734A1 (es) Anticuerpos monoclonales especificos del antigeno m del virus metapneumovirus humano (hmpv) y su uso en un metodo de diagnostico
SA518391078B1 (ar) (tslp) أجسام مضادة رابطة لليمفوبويتين السدوي الصعتري وطرق لاستخدام الأجسام المضادة
TR201907505T4 (tr) Anti-DR5 ailesi antikorları, bispesifik veya çok değerlikli anti-DR5 ailesi antikorları ve bunların kullanım yöntemleri.